HC Wainwright lowered the target on Eledon Pharmaceuticals(ELDN:NSD) to $25 from $35

STA Research
by: STA Research

HC Wainwright lowered the target on  Eledon Pharmaceuticals to $25 from $35 and maintained the Buy rating on the company’s stock.                                   

Based on the Eledon Pharmaceuticals Inc stock forecasts from 2 analysts, the average analyst target price for Eledon Pharmaceuticals Inc is USD 0.00 over the next 12 months. Eledon Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Eledon Pharmaceuticals Inc is Slightly Bullish , which is based on 3 positive signals and 2 negative signals. At the last closing, Eledon Pharmaceuticals Inc’s stock price was USD 5.09. Eledon Pharmaceuticals Inc’s stock price has changed by -0.56 % over the past week, +0.01 % over the past month and +0.00 % over the last year.

What to like:

Underpriced compared to book value The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason. Positive free cash flow The company had positive total free cash flow in the most recent four quarters. Superior Earnings Growth This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:

Low market capitalization This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future. Negative cashflow The company had negative total cash flow in the most recent four quarters.

 

 

Stock Target Advisor is not a broker/dealer, investment advisor or a platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information and education in order to help investors with their own research. No content in our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter in any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis

Leave a Reply

Your email address will not be published. Required fields are marked *